IFI44L and COVID-19: Eight further targets (CXCL6, IFI44, IFI44L, RSAD2, S100A8, SPRR2A, SYNE1, XAF1) associated with COVID-19 pathogenesis were identified but unfortunately we did not find approved or under trial drugs that could revert the alterations of these gene targets.